Mechanisms of thrombosis in hyperhomocysteinemia

Current Opinion in Hematology

Volumn 5, Issue 5, 1998, Pages 343-349

  Lentz, Steven R ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; HOMOCYSTEINE; PROTHROMBIN; VITAMIN B GROUP;

AMINO ACID METABOLISM; CELL CULTURE; ENDOTHELIUM; HEART INFARCTION; HUMAN; HYPERHOMOCYSTEINEMIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STROKE; VASCULAR SMOOTH MUSCLE; VEIN THROMBOSIS;

EID: 0031718236     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199809000-00007     Document Type: Review

References (79)

1. Mudd SH, Lew HL: Plasma homocyst(e)ine or homocysteine? N Engl J Med 1995, 333:325.
2. Mudd SH, Levy HL, Skovby F: Disorders of transsulfuration. In The Metabolic and Molecular Basis of Inherited Disease, edn 7. Edited by Scriver CR, Beaudet AL, Sly WS, Valle D. New York: McGraw-Hill, Inc. 1995:1279-1327.
3. Moghadasian MH, Mcmanus BM, Frohlich JJ: Homocyst(e)ine and coronary artery disease: clinical evidence and genetic and metabolic background. Arch Intern Med 1997, 157:2299-2308.
4. Dennis VW, Nurko S, Robinson K: Hyperhomocysteinemia: detection, risk assessment, and treatment. Curr Opin Nephrol Hypertens 1997, 6:483-488.
5. Ubbink JB: The role of vitamins in the pathogenesis and treatment of hyperhomocyst(e)inaemia. J Inher Metabol Dis 1997, 20:316-325.
6. Fowler B: Disorders of homocysteine metabolism. J Inher Metabol Dis 1997, 20:270-285.
7. Bostom AG, Lathrop L: Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 1997, 52:10-20.
8. Duell PB, Malinow MR: Homocyst(e)ine: an important risk factor for atherosclerotic vascular disease. Curr Opin Lipidol 1997, 8:28-34.
9. Refsum H, Ueland PM, Nygård O, Vollset SE: Homocysteine and cardiovascular disease. Annu Rev Med 1998, 49:31-62.
10. McCully KS: Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969, 56:111-128.
11. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, et al.: The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 1985, 37:1-31.
12. Clarke R, Daly L, Robinson K, Naughton E, Cahalane S, Fowler B, Graham I: Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991, 324:1149-1155.
13. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 1995, 274:1049-1057.
14. Graham IM, Daly LE, Refsum HM, Robinson K, Brattström LE, Ueland PM, et al.: Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. JAMA 1997, 277:1775-1781.
15. Nygård O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE: • Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997, 337:230-236. This prospective study of patients with angiographically confirmed coronary artery disease demonstrates that elevated plasma homocyst(e)ine concentration is a strong, graded risk factor for mortality.
16. Brattström L, Tengborn L, Lagerstedt C, Israelsson B, Hultberg B: Plasma homocysteine in venous thromboembolism. Haemostasis 1991, 21:51-57.
17. Bienvenu T, Ankri A, Chadefaux B, Montalescot G, Kamoun P: Elevated total plasma homocysteine, a risk factor for thrombosis: relation to coagulation and fibrinolytic parameters. Thromb Res 1993, 70:123-129.
18. Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci PM: High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb 1994, 14:1080-1083.
19. Fermo I, Vigano'D'Angelo S, Paroni R, Mazzola G, Calori G, D'Angelo A: Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med 1995, 123:747-753.
20. den Heijer M, Blom HJ, Gerrits WBJ, Rosendaal FR, Haak HL, Wijermans PW, Bos GMJ: Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet 1995, 345:882-885.
21. Amundsen T, Ueland PM, Waage A: Plasma homocysteine levels in patients with deep venous thrombosis. Arterioscler Thromfa Vasc Biol 1995, 15:1321-1323.
22. den Heijer M, Koster T, Blom HJ, Bos GMJ, Briet E, Reitsma PH, et al.: Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996, 334:759-762.
23. Simioni P, Prandoni P, Burlina A, Tormene D, Sardella C, Ferrari V, et al.: Hyperhomocysteinemia and deep-vein thrombosis: a case-control study. Thromb Haemost 1996, 76:883-886.
24. Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer • MJ: Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 1997, 95:1777-1782. In this large, prospective cohort analysis from the Physicians Health Study, apparently healthy men with hyperhomocysteinemia had increased risk of idiopathic venous thromboembolism. The risk of venous thromboembolism among men with coexistent hyperhomocysteinemia and the factor V Leiden mutation was far greater than the sum of the individual risks associated with either abnormality alone.
25. Freyburger G, Labrouche S, Sassoust G, Rouanet F, Javorschi S, Parrot F: Mild hyperhomocysteinemia and hemostatic factors in patients with arterial vascular diseases. Thromb Haemst 1997, 77:466-471.
26. D'Angelo A, Selhub J: Homocysteine and thrombotic disease. Blood 1997, 90:1-11.
27. Cattaneo M, Martinelli I, Faioni E, Franchi F, Zighetti ML, Mannucci PM: High plasma concentrations of activated protein C in patients with deep venous thrombosis and hyperhomocysteinemia. Br J Haematol 1996, 93(suppl 2):8.
28. Harpel PC, Chang VT, Borth W: Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci U S A 1992, 89:10193-10197.
29. Hajjar KA: Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 1993, 91:2873-2879.
30. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, Loscalzo J: Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993, 91:308-318.
31. Di Minno G, Davi G, Margaglione M, Cirillo F, Grandone E, Ciabattoni G, et al.: Abnormally high thromboxane biosynthesis in homozygous homocystinuria: evidence for platelet involvement and probucol-sensitive mechanism. J Clin Invest 1993, 92:1400-1406.
32. Durand P, Lussiercacan S, Blache D: Acute methionine load-induced •• hyperhomocysteinemia enhances platelet aggregation thromboxane biosynthesis, and macrophage-derived tissue factor activity in rats. FASEB J 1997, 11:1157-1168. In a rat model, acute methionine load-induced hyperhomocysteinemia was associated with increased platelet aggregation, increased tissue factor activity in peritoneal macrophages, and increased plasma concentration of lipid peroxidation products.
33. Upchurch GR, Welch GN, Fabian AJ, Freedman JE, Johnson JL, Keaney •• JF, Loscalzo J: Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997, 272:17012-17017. Treatment of bovine aortic endothelial cells with homocysteine resulted in decreased nitric oxide production and decreased glutathione peroxidase activity. These findings suggest that homocysteine may promote oxidative inactivation of nitric oxide by impairing the endothelial cell's ability to detoxify hydrogen peroxide.
34. Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM, Malinow MR, •• Heistad DD: Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest 1996, 98:24-29. The first study to demonstrate that moderate hyperhomocysteinemia is associated with impaired endothelium-dependent vasodilatation.
35. Zöller B, Hillarp A, Berntorp E, Dahlbäck B: Activated protein C resistance due to a common factor V gene mutation is a major risk factor for venous thrombosis. Annu Rev Med 1997, 48:45-58.
36. Celermajer DS, Sorensen K, Ryalls M, Robinson J, Thomas O, Leonard JV, Deanfield JE: Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents. J Am Coll Cardiol 1993, 22:854-858.
37. Tawakol A, Omland P, Gerhard M, Wu JT, Creager MA: •• Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997, 95:1119-1121. Impaired endothelium-dependent vasodilatation was demonstrated in humans with chronic moderate hyperhomocysteinemia.
38. Woo KS, Chook P, Lolin YI, Cheung ASP, Chan LT, Sun YY, et al.: • Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997, 96:2542-2544. Another recent study demonstrating that moderate hyperhomocysteinemia is associated with impaired endothelium-dependent vasodilatation in humans.
39. Bellamy MF, Mcdowell IFW: Putative mechanisms for vascular damage by homocysteine. J Inher Metabol Dis 1997, 20:307-315.
40. Kanani P, Sinkey CA, Knapp HR, Haynes WG: Experimental induction of moderate hyperhomocyst(e)inemia rapidly produces endothelial dysfunction in healthy humans [abstract]. Circulation 1997, 96:I-420.
41. Chambers RC, McGregor A, Jean-Marie J, Kooner JS: Acute hyperhomocysteinemia and endothelial dysfunction. Lancet 1998, 351:36-37.
42. Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, Lee ME: Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci U S A 1994, 91:6369-6373.
43. Tsai JC, Wang H, Perrella MA, Yoshizumi M, Sibinga NES, Tan LC, et al.: Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. J Clin Invest 1996, 97:146-153.
44. Nishio E, Watanabe Y: Homocysteine as a modulator of platelet-derived • growth factor action in vascular smooth muscle cells: a possible role for hydrogen peroxide. Br J Pharmacol 1997, 122:269-274. Experiments with cultured rat vascular smooth muscle cells demonstrated that homocysteine promotes cell proliferation and decreases glutathione peroxidase activity. This study suggests that homocysteine may stimulate growth of vascular smooth muscle through oxidative mechanisms.
45. Dalton ML, Gadson PF, Wrenn RW, Rosenquist TH: Homocysteine signal •• cascade: production of phospholipids, activation of protein kinase C, and the induction of c-fos and c-myb in smooth muscle cells. FASEB J 1997, 11:703-711. Experiments with cultured smooth muscle cells suggest that homocysteine promotes cell proliferation through activation of a receptor-mediated signal transduction pathway.
46. Lubec B, Labudova O, Hoeger H, Muehl A, Fang-Kircher S, Marx M, Mosgoeller W, Gialamas J: Homocysteine increases cyclin-dependent kinase in aortic rat tissue. Circulation 1996, 94:2620-2625.
47. Majors A, Ehrhart LA, Pezacka EH: Homocysteine as a risk factor for • vascular disease: enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol 1997, 17:2074-2081. This study found that homocysteine increased cell growth and collagen production in cultured rabbit aortic smooth muscle cells.
48. Welch GN, Upchurch GR Jr, Farivar RS, Pigazzi A, Vu K, Brecher P, et al.: • Homocysteine-induced nitric oxide production in vascular smooth-muscle cells by NF-kB-dependent transcriptional activation of Nos2. Proc Assoc Am Physicians 1998, 1:22-31. Homocysteine produced increased expression of the inducible nitric oxide synthase gene in cultured rat aortic smooth muscle cells. This suggests that hyperhomocysteinemia may induce or potentiate inflammatory responses in the vessel wall.
49. Kim W, Pae YS: Involvement of N-methyl-D-aspartate receptor and free radical in homocysteine-mediated toxicity on rat cerebellar granule cells in culture. Neurosci Lett 1996, 216:117-120.
50. Lipton SA, Kim WK, Choi YB, Kumar S, D'Emilia DM, Rayudu PV, et al.: •• Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci U S A 1997, 94:5923-5928. An important study demonstrating that homocysteine is an agonist for the N-methyl-D-aspartate (NMDA) receptor. This property of homocysteine may contribute to neurotoxicity associated with stroke, and also may mediate some of the effects of homocysteine on vascular cells
51. Lentz SR: Homocysteine and vascular dysfunction. Life Sci 1997, 61:1205-1215.
52. Loscalzo J: The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 1996, 98:5-7.
53. Glaser CB, Morser J, Clarke JH, Blasko E, McLean K, Kuhn I, et al.: Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity: a potential rapid mechanism for modulation of coagulation. J Clin Invest 1992, 90:2565-2573.
54. Starkebaum G, Harlan JM: Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986, 77:1370-1376.
55. Parthasarathy S: Oxidation of low density lipoprotein by thiol compounds leads to its recognition by the acetyl LDL receptor. Biochim Biophys Acta 1987, 917:337-340.
56. Heinecke JW, Rosen H, Suzuki LA, Chait A: The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem 1987, 262:10098-10103.
57. Jones BG, Rose FA, Tudball N: Lipid peroxidation and homocysteine induced toxicity. Atherosclerosis 1994, 105:165-170.
58. Halvorsen B, Brude I, Drevon CA, Nysom J, Ose L, Christiansen EN, Nenseter MS: Effect of homocysteine on copper ion-catalyzed, azo compound-initiated, and mononuclear cell-mediated oxidative modification of low density lipoprotein. J Lipid Res 1996, 37:1591-1600.
59. Blom HJ, Engelen DP, Boers GH, Stadhouders AM, Sengers RC, de Abreu R, et al.: Lipid peroxidation in homocysteinaemia. J Inher Metabol Dis 1992, 15:419-22.
60. Dudman NPB, Wilcken DEL, Stocker R: Circulating lipid hydroperoxide levels in human hyperhomocysteinemia: relevance to development of arteriosclerosis. Arterioscler Thromb 1993, 13:512-516.
61. Cordoba-Porras A, Sanchez-Quesada JL, Gonzalez-Sastre F, Ordonez-Llanos J, Blanco-Vaca F: Susceptibility of plasma low- and high-density lipoproteins to oxidation in patients with severe hyperhomocysteinemia. J Mol Med 1996, 74:771-776.
62. Domagala TB, Libura M, Szczeklik A: Hyperhomocysteinemia following oral • methionine load is associated with increased lipid peroxidation. Thromb Res 1997, 87:411-416. This study found that methionine load-induced hyperhomocysteinemia was associated with increased lipid peroxidation in human volunteers.
63. Durand P, Prost M, Blache D: Pro-thrombotic effects of a folic acid deficient diet in rat platelets and macrophages related to elevated homocysteine and decreased n-3 polyunsaturated fatty acids. Atherosclerosis 1996, 121:231-243.
64. Young PB, Kennedy S, Molloy AM, Scott JM, Weir DG, Kennedy DG: Lipid • peroxidation induced in vivo by hyperhomocysteinaemia in pigs. Atherosclerosis 1997, 129:67-71. Elevated levels of lipid peroxidation products are demonstrated in cardiac tissue in a pig model of severe hyperhomocysteinemia.
65. Finkelstein JD, Martin JJ: Methionine metabolism in mammals: adaptation to methionine excess. J Biol Chem 1986, 261:1582-1587.
66. Selhub J, Miller JW: The pathogenesis of homocysteinemia: interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr 1992, 55:131-138.
67. Wang H, Yoshizumi M, Lai KH, Tsai JC, Perrella MA, Haber E, Lee ME: •• Inhibition of growth and p21(ras) methylation in vascular endothelial cells by homocysteine but not cysteine. J Biol Chem 1997, 272:25380-25385. This interesting study found that homocysteine, but not cysteine, inhibited DNA synthesis and decreased methylation of the guanine nucleotide binding protein Ras in cultured endothelial cells.
68. Vallance P, Leone A, Calver A, Collier J, Moncada S: Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 1992, 20(Suppl 12):S60-S62.
69. Lentz SR, Malinow MR, Piegors DJ, Bhopatkar-Teredesai M, Faraci FM, Heistad DD: Consequences of hyperhomocyst(e)inemia on vascular function in atherosclerotic monkeys. Arterioscl Thromb Vasc Biol 1997, 17:2930-2934.
70. Rolland PH, Friggi A, Barlatier A, Piquet P, Latrille V, Faye MM, Guillou J, Charpiot P, Bodard H, Ghiringhelli O, Calaf R, Luccioni R, Garcon D: Hyperhomocysteinemia-induced vascular damage in the minipig: captoprilhydrochlorothiazide combination prevents elastic alterations. Circulation 1995, 91:1161-1174.
71. Rodgers GM, Kane WH: Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest 1986, 77:1909-1916.
72. Rodgers GM, Conn MT: Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 1990, 75:895-901.
73. Lentz SR, Sadler JE: Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991, 88:1906-1914.
74. Hayashi T, Honda G, Suzuki K: An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells. Blood 1992, 79:2930-2936.
75. Lentz SR, Sadler JE: Homocysteine inhibits von Willebrand factor processing and secretion by preventing transport from the endoplasmic reticulum. Blood 1993, 81:683-689.
76. Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers GM: Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb 1993, 13:1327-1333.
77. Nishinaga M, Ozawa T, Shimada K: Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest 1993, 92:1381-1386.
78. Wang J, Dudman NPB, Wilcken DEL: Effects of homocysteine and related compounds on prostacyclin production by cultured human vascular endothelial cells. Thromb Haemost 1993, 70:1047-1052.
79. Kokame K, Kato H, Miyata T: Homocysteine-respondent genes in vascular endothelial cells identified by differential display analysis: GRP78/BiP and novel genes. J Biol Chem 1996, 271:29659-29665.